<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Several of these diseases, such as <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs), are responsive to DNA methyltransferase inhibitors </plain></SENT>
<SENT sid="2" pm="."><plain>To determine the extent of promoter hypermethylation in such <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, we compared the distribution of DNA methylation of 14 000 promoters in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients enrolled in a phase 1 trial of <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> and the <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor entinostat against de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> CD34(+) bone marrow cells </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> patients displayed more extensive aberrant DNA methylation involving thousands of genes than did the <z:mpath ids='MPATH_458'>normal</z:mpath> CD34(+) bone marrow cells or de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts </plain></SENT>
<SENT sid="4" pm="."><plain>Aberrant methylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> tended to affect particular chromosomal regions, occurred more frequently in Alu-poor genes, and included prominent involvement of genes involved in the WNT and MAPK signaling pathways </plain></SENT>
<SENT sid="5" pm="."><plain>DNA methylation was also measured at days 15 and 29 after the first treatment cycle </plain></SENT>
<SENT sid="6" pm="."><plain>DNA methylation was reversed at day 15 in a uniform manner throughout the genome, and this effect persisted through day 29, even without continuous administration of the study drugs </plain></SENT>
<SENT sid="7" pm="."><plain>This trial was registered at www.clinicaltrials.gov as J0443 </plain></SENT>
</text></document>